Patent ID: 11913075
Assignee: DANA-FARBER CANCER INSTITUTE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC C

Claim 4:
5. A method of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent comprising a small molecule CDK4/6 inhibitor selected from the group consisting of abemaciclib, palbociclib, and ribociclib,
wherein the subject was treated with immune checkpoint inhibitors (ICI) and is resistant, and
wherein the subject has a solid tumor that expresses an ICR gene signature in malignant cells, said gene signature comprising upregulation of C1QBP, CCT2, CCT6A, DCAF13, EIF4A1, ILF2, MAGEA4, NONO, PA2G4, PGAM1, PPA1, PPIA, RPL18A, RPL26, RPL31, RPS11, RPS15, RPS21, RPS5, RUVBL2, SAE1, SNRPE, UBA52, UQCRH and VDAC2; and, optionally, downregulation of AEBP1, AHNAK, APOC2, APOD, APOE, B2M, C10orf54, CD63, CTSD, EEA1, EMP1, FBXO32, FYB, GATSL3, HCP5, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-H, ITGA3, LAMP2, LYRM9, MFGE8, MIA, NPC2, NSG1, PROS1, RDH5, SERPINA1, TAPBP, TIMP2, TNFSF4 and TRIML2, as compared to a reference level.